Bibliographic Details
| Title: |
Uremic Toxins and Vascular Dysfunction |
| Authors: |
Isabelle Six, Nadia Flissi, Gaëlle Lenglet, Loïc Louvet, Said Kamel, Marlène Gallet, Ziad A. Massy, Sophie Liabeuf |
| Source: |
Toxins, Vol 12, Iss 6, p 404 (2020) |
| Publisher Information: |
MDPI AG, 2020. |
| Publication Year: |
2020 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
chronic kidney disease, uremic toxins, vascular dysfunction, Medicine |
| More Details: |
Vascular dysfunction is an essential element found in many cardiovascular pathologies and in pathologies that have a cardiovascular impact such as chronic kidney disease (CKD). Alteration of vasomotricity is due to an imbalance between the production of relaxing and contracting factors. In addition to becoming a determining factor in pathophysiological alterations, vascular dysfunction constitutes the first step in the development of atherosclerosis plaques or vascular calcifications. In patients with CKD, alteration of vasomotricity tends to emerge as being a new, less conventional, risk factor. CKD is characterized by the accumulation of uremic toxins (UTs) such as phosphate, para-cresyl sulfate, indoxyl sulfate, and FGF23 and, consequently, the deleterious role of UTs on vascular dysfunction has been explored. This accumulation of UTs is associated with systemic alterations including inflammation, oxidative stress, and the decrease of nitric oxide production. The present review proposes to summarize our current knowledge of the mechanisms by which UTs induce vascular dysfunction. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2072-6651 |
| Relation: |
https://www.mdpi.com/2072-6651/12/6/404; https://doaj.org/toc/2072-6651 |
| DOI: |
10.3390/toxins12060404 |
| Access URL: |
https://doaj.org/article/eb1b4c37a0b548468bcd6ae8538dd125 |
| Accession Number: |
edsdoj.b1b4c37a0b548468bcd6ae8538dd125 |
| Database: |
Directory of Open Access Journals |
|
Full text is not displayed to guests. |
Login for full access.
|
